Taking lessons from dendritic cells: Multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity

Gene Therapy

Volumn 6, Issue 11, 1999, Pages 1835-1844

  Kanwar, J R ^a   Berg, R W ^a   Lehnert, K ^a   Krissansen, G W ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cancer; Cancer gene therapy; Cytolytic T cells; NK cells; Systemic anti tumor immunity; Xenogeneic costimulatory integrin ligands

Indexed keywords

CELL ADHESION MOLECULE; FAS LIGAND; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; PERFORIN; UVOMORULIN; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; GENE TRANSFER; IMMUNIZATION; LEUKOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALIA;

EID: 0032736478     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301016     Document Type: Article

References (43)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 39: 245-252.
2. Gao JX et al. Generation of dendritic cell-like antigen-presenting cells in long-term mixed leucocyte culture: phenotype and functional studies. Immunol 1997; 91: 135-144.
3. Koopman G et al. Adhesion of human B cells to follicular dendritic cells involves both the lymphocyte function-associated antigen 1/intercellular adhesion molecule 1 and very late antigen 4/vascular cell adhesion molecule 1 pathways. J Exp Med 1992; 173: 1297-1304.
4. Cumberbatch M, Dearman RJ, Kimber I. Adhesion molecule expression by epidermal Langerhans cells and lymph node dendritic cells: a comparison. Arch Derm Res 1996; 288: 739-744.
5. Starling GC et al. Intercellular adhesion molecule-3 is the predominant co-stimulatory ligand for leukocyte function antigen-1 on human blood dendritic cells. Eur J Immunol 1995; 25: 2528-2532.
6. Szabo MC, Butcher EC, McEvoy LM. Specialization of mucosal follicular dendritic cells revealed by mucosal addressin-cell adhesion molecule-1 display. J Immunol 1997; 158: 5584-5588.
7. Debenedette MA, Shahinian A, Mak TW, Watts TH. Costimulation of CD28-lymphocytes by 4-1BB ligand. J Immunol 1997; 158: 551-559.
8. Anderson DM et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-179.
9. Bordello F, Lederer J, Scott S, Sharpe AH. MRC OX-2 defines a novel T cell costimulatory pathway. J Immunol 1997; 158: 4548-4554.
10. Ebner S et al. Expression of maturation-/migration-related molecules on human dendritic cells from blood and skin. Immunobiol 1998; 198: 568-587.
11. Nestle FO et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nature Med 1998; 4: 328-332.
12. + T cells by B7 transfected melanoma cells. Science 1993; 259: 368-370.
13. Chen L et al. Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
14. Baskar S et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated MHC class II molecules. Prac Natl Acad Sci USA 1993; 90: 5687-5690.
15. Hodge JW, Abrams S, Schlom J, Kantor JA. Induction of anti-tumor immunity by recombinant vaccinia viruses expressing B7.1 or B7.2 costimulatory molecules. Cancer Res 1994; 54: 5552-5555.
16. Wei K et al. Xenogeneic ICAM-1 gene transfer suppresses tumorigenicity and generates protective antitumor immunity. Gene Therapy 1996; 3: 531-541.
17. Melero I et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway. Eur J Immunol 1998; 28: 1116-1121.
18. Lehnert K, Print CG, Yang Y, Krissansen GW. Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) costimulates T cell proliferation exclusively through integrin α4β7 (LPAM-1), whereas VCAM-1 and CS-1 peptide use α4β1 (VLA-4): evidence for 'remote' costimulation and induction of hyperresponsiveness to B7 molecules. Eur J Immunol 1998; 28: 3605-3615.
19. Berg RW, Yang Y, Lehnert K, Krissansen GW. Mouse M290 is the functional homologue of the human mucosal lymphocyte integrin HML-1: antagonism between the integrin ligands E-cadherin and RGD tripeptide. Immunol Cell Biol (in press).
20. Yang J-P, Huang I. Direct gene transfer to mouse melanoma by intratumor injection of free DNA. Gene Therapy 1996; 3: 542-548.
21. Katsanis E et al. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing. Cancer Immunol Immunother 1994; 38: 135-141.
22. Naftzger C et al. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and auto-immunity' Proc Natl Acad Sci USA 1996; 93: 14809-14814.
23. Fakhari H et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc Natl Acad Sci USA 1996; 93: 2909-2914.
24. Strand S et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - mechanism of immune evasion? Nature Med 1996; 2: 1361-1366.
25. Zeytun A, Hassuneh M, Nagarkatti M, Nagarkatti PS. Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street. Blood 1997; 90: 1952-1959.
26. Lefor AT, Fabian DF. Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model. J Surg Res 1998; 75: 49-53.
27. Anichini A, Mortarini R, Supino R, Parmiani G. Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype, VLA profile and invasive ability. Int J Cancer 1990; 46: 508-515.
28. Naganuma H et al. Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells, Int J Cancer 1991; 47: 527-532.
29. Nishio M et al. CD80 (B7.1) and CD54 (intracellular adhesion molecule-1) induce target susceptibility to promiscuous cytotoxic T cell lysis. J Immunol 1996; 157: 4347-4353.
30. Komatsu F, Kajiwara M. A lymphokine-activated killer (LAK)-resistant cell line, and low expression of adhesion molecules LFA-3 and VCAM-1 on its cell surface. Oncology Res 1998; 10: 263-269.
31. Damle NK et al. Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7. J Immunol 1994; 152: 2686-2697.
32. Felzmann T, Ramsey WJ, Blaese RM. Anti-tumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer. Cancer Lett 1999; 135: 1-10.
33. Cavallo F et al. Co-expression of B7.1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol 1995; 25: 1154-1162.
34. Matulonis U et al. B7.1 is superior to B7.2 costimulation in the induction and maintenance of T cell-mediated antileukaemia immunity. J Immunol 1996; 156: 1126-1131.
35. Nishio M, Podack ER. Rapid induction of tumor necrosis factor cytotoxicity in naive splenic T cells by simultaneous CD80 (B7.1) and CD54 (ICAM-1) co-stimulation. Eur Immunol 1996; 26: 2160-2164.
36. Masinovsky B et al. IL-4 acts synergistically with IL-1 beta to promote lymphocyte adhesion to microvascular endothelium by induction of vascular cell adhesion molecule-1. J Immunol 1990; 145: 2886-2895.
37. Berlin C et al. α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 1993; 74: 185-195.
38. Leung E et al. Cloning of the mucosal addressin MAdCAM-1 from human brain: identification of novel alternatively spliced transcripts. Immunol Cell Biol 1996; 74: 490-496.
39. Freeman GJ et al. Cloning of B7.2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993; 262: 909-911.
40. Briskin MJ, McEvoy LM, Butcher EC. MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1. Nature 1993; 363: 461-464.
41. Nagafuchi A et al. Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA. Nature 1987; 329: 341-343.
42. Rimm DL, Morrow JS. Molecular cloning of human E-cadherin suggests a novel subdivision of the cadherin superfamily. Biochem Biophys Res Commun 1994; 200: 1754-1761.
43. Azmi M, Field HJ. Cell-mediated antiviral response to equine herpesvirus type 1 demonstrated in a murine infection model by means of adoptive transfer of immune cells. J Gen Virol 1993; 74: 275-280.